In Brief:
In an updated systematic review and meta-analysis of controlled trials regarding treatment of antibody-mediated rejection, the authors outline the overall low quality of data (heterogeneity), the current standard of care (plasma exchange + IVIg) and the difficulties drawing conclusions about the efficacy of rituximab, bortezomib, and eculizumab.
Go to Full Text of this Article